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Summary Two hundred and seventy-eight adult chemonaive patients receiving moderately emetogenic
chemotherapy were randomly allocated to receive either intravenous (i.v.) granisetron 3 mg plus i.v. dexa-
methasone 8 mg or i.v. granisetron 3 mg plus i.v. placebo dexamethasone prior to chemotherapy. Eighty-two
per cent of all patients recruited were female, and 91% of all patients consumed less than 10 units of alcohol
per week, suggesting a study population with an increased risk of nausea and vomiting. In the first 24 h 85%
of patients who received granisetron plus dexamethasone were complete responders compared with 75.9% of
the patients receiving granisetron alone (P = 0.053). There were statistically significant improvements in
complete response over 7 days (P = 0.029) and in the numbers of patients receiving rescue antiemetic
(P = 0.0004). Toxicity was minimal with no significant differences between treatment groups. These results
confirm the antiemetic activity of granisetron and show that it has an additive effect in combination with
dexamethasone.
As single agents the 5HT3 antagonists granisetron (Marty,
1992; Chevallier, 1993) ondansetron (De Mulder, 1990) and
tropisetron (De Bruijn, 1992) have been shown to be at least
as effective as conventional treatments in controlling the
acute nausea and vomiting experienced by patients receiving
highly emetogenic chemotherapeutic regimens. Furthermore,
they have an improved safety profile. There is now evidence
indicating that the addition of a corticosteroid to ondanset-
ron further enhances its efficacy in the acute phase (Roila,
1991; Smyth, 1991), although to date there are no similar
data for granisetron.
The management of delayed emesis, however, remains less
than satisfactory with existing therapies, with around 50% of
patients remaining uncontrolled (Kris, 1989). The combina-
tion of metoclopramide and dexamethasone has been shown
to be better than either dexamethasone or placebo (Kris,
1989; Moreno, 1992). However, the place of 5HT3 an-
tagonists in the management of delayed emesis is as yet
unclear. Indeed, oral ondansetron alone has not been demon-
strated to be superior to either dexamethasone (Jones, 1991)
or metoclopramide (De Mulder, 1990). The objective of this
study was therefore to compare the safety and efficacy of
intravenous granisetron plus dexamethasone phosphate with
that of intravenous granisetron alone in the prevention of
both acute and delayed emesis induced by moderately
emetogenic cytotoxic chemotherapy.
Patients and methods
Study design
The study was a double-blind, randomised, parallel group
study carried out at 18 centres in the UK. Patients gave their
witnessed written or verbal informed consent to participate in
the study and were informed that they were free to withdraw
at any time. The study was performed in accordance with
good clinical practice guidelines. Patients were eligible if they
were over the legal age of consent, had malignant disease,
were chemotherapy naive and had a score of 2 or less on the
WHO performance status scale. Patients were excluded if
they had marked hepatic or renal dysfunction, an active
peptic ulcer or gastric compression or had experienced
moderate/severe nausea or vomiting in the week prior to
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chemotherapy. Patients scheduled to receive any other
antiemetic drugs or concomitant radiotherapy during the
study period were also excluded.
Cytotoxic chemotherapy regimens
Patients received at least one of the following cytotoxic
drugs: carboplatin > 300 mg m2, cisplatin 20-50 mg
dacarbazine 350-500 mg m-2, cyclophosphamide > 500 mg
m 2 (in combination), doxorubicin>40mgm2 (single
agent), doxorubicin> 25 mg m-2 (in combination), epirubicin
>75mgm2 (single agent) or epirubicin >50mgm2 (in
combination).
Antiemetic treatment
Patients were screened and randomly allocated (using a
computer-generated randomisation list) to treatment with a
5 min infusion of intravenous (i.v.) granisetron 3 mg
(administered 5 min before chemotherapy) and a 5 min
infusion of either i.v. dexamethasone phosphate 8 mg or i.v.
dexamethasone phosphate placebo (administered 10 min
before chemotherapy).
Rescue medication
If control of emesis was not obtained with the study medica-
tion, patients were permitted to take additional therapy as
necessary. Oral metoclopramide was administered as take-
home antiemetic therapy in the event of moderate or severe
nausea and/or vomiting.
Efficacy assessment
Patients were discharged shortly after chemotherapy was
completed, and given diary cards on which to record their
symptoms of nausea and vomiting over the next 7 days.
Efficacy was evaluated from the subjective assessment of the
severity of nausea (recorded as none, mild, moderate or
severe) and the number of episodes of vomiting recorded by
the patients daily. After 7 days, unused medication and
completed diary cards were returned.
Clinical and laboratory monitoring
A full clinical history and examination was carried out at
screening. In addition, haematological and clinical chemistry
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parameters were measured and repeated at the follow-up visit
on day 7. Changes in haematological and clinical chemistry
parameters from baseline were flagged if they were above or
below the reference range, and double flagged if, in addition,
the measured changes exceeded a predetermined amount
from baseline. For haematological parameters a single flag
was recorded for -2.0 g dl-' haemoglobin, -0.7 x 1012 1-l
RBC and -0.05 for packed cell volume ratio, -100 x 1091-'
platelets and - 5.0 x 109 1' WBC. For alkaline phosphatase,
values received a double flag if they were 1.75 times the
upper limit of the reference range and ALT and AST if twice
the upper limit of the reference range.
Adverse events were recorded at each visit and classed by
the clinician according to their intensity. They were described
as serious if they were fatal, life-threatening, disabling or
incapacitating or resulted in hospitalisation or prolonged a
hospital stay.
Efficacy analysis
Efficacy data were analysed for all patients who received at
least one dose of randomised study medication and had at
least one post-dose assessment. Efficacy analyses were based
on complete response, total control and survival analyses.
Complete response was defined as a patient who had no
vomiting, no worse than mild nausea, received no rescue
therapy and was not withdrawn on day 0 (day of chemo-
therapy) and within the 7 day study period. Total control
was defined as a patient who had no vomiting, no nausea,
received no rescue therapy and was not withdrawn on day 0
and over the 7 day period. Log-rank event analyses were
conducted over the 7 day period for times to first events of
vomiting, moderate/severe nausea and receipt of rescue
therapy over the 7 day period.
Statistical analysis
The chi-squared test (significance level 5%) was used to test
for differences between treatment groups; logistic regression
(significance level 10%) to investigate a significant treatment
interaction between subgroups; and the Cox log-rank test
(significance level 5%) to test for a difference in the log-rank
event distributions over the 7 day period.
Results
A total of 278 patients were enrolled into the study and were
randomly allocated to one of the two treatment groups; 141
received granisetron plus dexamethasone and 137 received
granisetron plus placebo. Demographic data for all patients
are shown in Table I.
The majority (81.7%) of patients were female. However,
the ratio of male to female patients differed by about 10%
between treatment groups. Ninety-one per cent of all patients
consumed fewer than 10 units of alcohol per week. The mean
dose of each main cytostatic drug and a summary of the
numbers of patients receiving each drug are shown in Table
II. Cyclophosphamide was the most common cytostatic drug
used. The most common primary disease site was the breast:
48% in the granisetron/dexamethasone group and 44% in
the granisetron placebo group.
Complete response
In the first 24 h, 120/141 (85.1%) patients in the granisetron/
dexamethasone group and 104/137 (75.9%) in the grani-
setron/placebo group were complete responders. Over the 7
day period 60/141 (42.6%) in the former group compared
with 41/137 (29.9%) in the latter group maintained a com-
plete response. The difference between treatment groups ap-
proached significance over the first 24 h (P = 0.053) and was
statistically significant when assessed over the 7 day period
(P = 0.029). Complete response was analysed by subgroups
of sex, age group,- time of administration of chemotherapy,
Table I Demographic data
Treatment group
Gran/dex Gran/placebo
Demography characteristic (n= 141) (n= 137)
Male 19 (13.5%) 32 (23.4%)
Female 122 (86.5%) 105 (76.6%)
Mean age (years) 54.17 52.13
Age range (years) 22-79 25-75
< 10 units alcohol per week 129 (91.5%) 124 (90.5%)
Table II Mean dose of main cytostatic therapy (mgm2)
Mean dose
Main cytostatic drug Gran/dex Gran/placebo
(specified range) (mg m-2) (mgm-2)
Cyclophosphamide 614.95 (n = 76) 613.32 (n = 68)
Carboplatin 377.53 (n = 38) 381.08 (n = 38)
Cisplatin 46.01 (n = 11) 49.40 (n = 15)
Doxorubicin 41.47 (n = 9) 50.97 (n = 10)
Epirubicin 97.16 (n = 6) 84.65 (n = 5)
Mitoxantrone None 13.31 (n = 1)
weekly consumption of alcohol, cancer type and main
chemotherapeutic agent. No statistically significant treatment
by factor interactions were observed.
Total control
Total control of symptoms was achieved by 103/141 (73%)
patients in the granisetron/dexamethasone group compared
with 82/137 (59.9%) in the granisetron/placebo group within
the first 24 h. Over the 7 day period total control was
achieved by 39/141 (27.7%) patients in the former group and
22/137 (16.1%) patients in the latter group. The difference
between treatment groups was statistically significant both
after 24 h (P = 0.020) and over the 7 day period
(P = 0.019).
Time to.first vomiting
Figure 1 shows the distribution curves for the first episode of
vomiting in each treatment group. During the 7 day period
37 (26.8%) patients in the granisetron/dexamethasone group
experienced vomiting, compared with 57 (41.9%) in the
granisetron/placebo group (Kaplan-Meier estimates). This
difference was statistically significant (P = 0.006). The
number of patients who vomited was slightly higher in the
granisetron/placebo group on each day of the period.
The greatest number of patients in both treatment groups
first vomited on day 2: 22 patients in the granisetron/
dexamethasone group and 37 in the granisetron/placebo
group. Of the former group one patient had more than four
episodes of vomiting, while ten had only one episode of
vomiting on that day. Of the latter group, none of the
patients had more than four episodes on that day and 24 had
only one episode. The most severe vomiting (i.e. more than
four episodes) in the granisetron/placebo group occurred in
four patients on day 1, while in the granisetron/dexa-
methasone group it occurred on days 1 (one patient) and 2
(one patient).
Time to first episode ofmoderate/severe nausea
Figure 2 shows the distribution curves for the first episode of
moderate/severe vomiting in each treatment group. During
the 7 day period 49 (35.5%) patients in the granisetron/
dexamethasone group experienced moderate or severe nausea
compared with 64 (47%) of patients in the granisetron/
placebo group (Kaplan-Meier estimates). This difference
between treatment groups was statistically significant
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Figure 1 Time to first vomiting episode over 7 days. Treatment
group: , granisetron + dexamethasone; * * *, granisetron + -
placebo.
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Figure 2 Time to any rescue medication over 7 days. Treatment
group: , granisetron + dexamethasone; , granisetron + -
placebo.
moderate/severe nausea was slightly higher in the
granisetron/placebo group on each day of the period.
Time to rescue therapy
Figure 3 shows the distribution for the receipt of rescue
medication in each treatment group. At the end of the 7 day
period 47% of patients in the granisetron/dexamethasone
group had received rescue therapy compared with 65% of
patients in the granisetron/placebo group (Kaplan-Meier
estimates); this was statistically significant (P<0.001).
Sqity, assessment
The number of double-flagged laboratory parameters was
low (less than 2%) and similar in both groups. Adverse
events occurring in 5% or more patients in either treatment
group are shown in Table III. With the exception of taste
perversion, there were no statistically significant differences
between the treatment groups. Taste perversion was found to
occur in significantly more patients in the granisetron/
placebo group (7%) than in the granisetron/dexamethasone
group (2%) (P=0.041).
Seven (4.3%) patients in the granisetron/dexamethasone
group experienced events considered to be severe, compared
with 20 (14.6%) in the granisetron/placebo group. The most
common severe adverse events were constipation and
headache. There were no significant adverse events leading to
withdrawal from the study in either group. Three patients in
the granisetron/dexamethasone group and seven in the
granisetron/placebo group had adverse events reported as
serious. However, none was considered to be related to study
therapy.
Discussion
This study compared the antiemetic efficacy of a single dose
of granisetron plus dexamethasone with that of a single dose
of granisetron alone over a 7 day period following
Figure 3 Time to first moderate/severe nausea episode over 7
days. Treatment group: , granisetron + dexamethasone;
granisetron + placebo.
Table III Most common adverse events [number (%) of patients]
Adverse event by
preferred term Gran/dex Gran/placebo
No. of patients with at 91 (64.5%) 92 (67.2%) P = NS
least one event
Constipation 28 (19.9%) 34 (24.8%) P = NS
Headache 25 (17.7%) 29 (21.2%) P = NS
Asthenia 21 (14.9%) 13 (9.5%) P =NS
Leucopenia 14 (9.9%) 19 (13.9%) P =NS
Diarrhoea 8 (5.7%) 7 (5.1%) P =NS
Decreased appetite 7 (5.0%) 6 (4.4%) P =NS
Dizziness 9 (6.4%) 6 (4.4%) P = NS
Taste perversion 3 (2.1%) 10 (7.3%) P = 0.041
moderately emetogenic chemotherapy. Our results demon-
strate that granisetron/dexamethasone was statistically
superior to granisetron/placebo in terms of total control,
time to first vomiting, time to first episode of moderate/
severe nausea and rescue therapy over the 7 day period
following chemotherapy. Furthermore, the proportion of
patients who had a complete response was higher in the
granisetron/dexamethasone group than in the granisetron/
placebo group. This difference approached statistical
significance within the first 24 h and reached statistical
significance over the 7 day period. The results for granisetron
alone are completely in line with other work, which has
shown a complete response rate of 70% following moderately
emetogenic chemotherapy (Marty, 1990). Control of emesis is
more difficult to achieve in females than in males (Walsh,
1982, Raoila, 1985) and in low alcohol consumers than in
high alcohol consumers (D'Acquisito, 1986). It is interesting
to note, therefore, that our study population was at high risk
of gastrointestinal toxicity in that 81.7% were female and
91% were low alcohol consumers. Although the place of
5HT3 antagonists in managing acute emesis is indisputable,
their place in the management of delayed emesis is yet to be
established. Indeed, it has been suggested that their routine
use in delayed emesis be discouraged on both scientific and
economic grounds (Kaye, 1993). However, while the underly-
ing mechanisms of delayed emesis are little understood, it is
well known that the adequacy of control within the first 24 h
will have a significant effect on the extent of delayed emesis.
Our data confirm the hypothesis that the addition of a single
dexamethasone dose further enhances the efficacy ofgraniset-
ron and demonstrate that this improved efficacy may be
sustained over a period of up to 7 days.
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